C2T-admin

/C2T-admin

About C2T-admin

This author has not yet filled in any details.
So far C2T-admin has created 16 blog entries.

C2 Therapeutics Receives FDA Clearance

2017-05-16T21:29:58+00:00

C2 Therapeutics’ Receives FDA Clearance for Next Generation Cryoballoon Ablation System

Redwood City, Calif. – August 22, 2013 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus), today announced that it received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Cryoballoon Focal Ablation System.  This is the company’s second 510(k) clearance and will be working to introduce Cryoballoon ablation in the United States.  nitial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation …

Click here to see full release.

C2 Therapeutics Receives FDA Clearance 2017-05-16T21:29:58+00:00

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment

2017-08-28T19:48:57+00:00

West Penn Allegheny Health System researchers are investigating whether a new ablation technology can provide safer and more effective treatment for patients with Barrett’s Esophagus, a condition associated with gastroesophageal reflux disease (GERD) that can progress to esophageal cancer if left untreated.

Click here for the full story.

West Penn Allegheny Clinical Trial Tests New Barrett’s Esophagus Treatment 2017-08-28T19:48:57+00:00

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

2017-05-16T21:29:58+00:00

C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

Click here for full release.

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial 2017-05-16T21:29:58+00:00

DDW2012

2017-05-16T21:29:58+00:00

Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation

The abstract, Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation (1299398) will be presented during the 53rd Annual Meeting of The Society for Surgery of the Ailmentary Tract (SSAT) in conjunction with DDW at the San Diego Convention Center in San Diego, California.

The abstract can be viewed here: http://meetings.ssat.com/abstracts/2012/QS17.cgi

DDW2012 2017-05-16T21:29:58+00:00

Start-up Uses Freezing Balloon to Treat Pre-Cancerous Esophagus

2017-05-16T21:29:58+00:00

Redwood City-based C2Therapeutics is hoping to kill diseased tissue in people’s esophaguses before it becomes one of the most deadly cancers of the human body.  For the 40 million Americans with acid reflux disease, treatment is often over the counter medication or a simple change in diet. However, one in five with acid reflux will likely develop Barrett’s Esophagus, a pre-cancerous condition that makes patients 30 to 125 times more likely to develop cancer of the esophagus.  See Complete Story.

Start-up Uses Freezing Balloon to Treat Pre-Cancerous Esophagus 2017-05-16T21:29:58+00:00

Preclinical Testing Complete

2017-05-16T21:29:58+00:00

The CryoBalloon device enables circumferential mucosal ablation in a 1-step process by using a novel, through-the-scope balloon. The maximal effect on the mucosa is achieved with a 12-second application time. Because of its ease of use, this new device merits further study so that we can find its possible role in the treatment of Barrett’s esophagus.

Read the full abstract here.

Preclinical Testing Complete 2017-05-16T21:29:58+00:00